Byron Martina
Overview
Explore the profile of Byron Martina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lang J, Dutta S, Leuthold M, Reichert L, Kuhl N, Martina B, et al.
Antiviral Res
. 2024 Dec;
234():106053.
PMID: 39645089
The viral NS2B-NS3 protease is a promising drug target to combat dengue virus (DENV) and other emerging flaviviruses. The discovery of novel DENV protease inhibitors with antiviral efficacy is hampered...
2.
Rothen D, Dutta S, Krenger P, Vogt A, Lieknina I, Sobczak J, et al.
Vaccines (Basel)
. 2024 Oct;
12(10).
PMID: 39460367
The authors would like to make the following corrections to this published paper [...].
3.
Rothen D, Dutta S, Krenger P, Pardini A, Vogt A, Josi R, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340083
Declared as a Public Health Emergency in 2016 by the World Health Organization (WHO), the Zika virus (ZIKV) continues to cause outbreaks that are linked to increased neurological complications. Transmitted...
4.
Rothen D, Dutta S, Krenger P, Vogt A, Lieknina I, Sobczak J, et al.
Vaccines (Basel)
. 2024 Aug;
12(8).
PMID: 39204000
Over the past few decades, dengue fever has emerged as a significant global health threat, affecting tropical and moderate climate regions. Current vaccines have practical limitations, there is a strong...
5.
Sobczak J, Barkovska I, Balke I, Rothen D, Mohsen M, Skrastina D, et al.
Vaccines (Basel)
. 2024 Jun;
12(6).
PMID: 38932390
T help (Th), stimulation of toll-like receptors (pathogen-associated molecular patterns, PAMPs), and antigen organization and repetitiveness (pathogen-associated structural patterns, PASPs) were shown numerous times to be important in driving B-cell...
6.
Nainggolan L, Dewi B, Hakiki A, Pranata A, Sudiro T, Martina B, et al.
PLoS One
. 2023 May;
18(5):e0285087.
PMID: 37130105
Objectives: Plasma leakage, a hallmark of disease in Dengue virus (DENV) infection, is an important clinical manifestation and is often associated with numerous factors such as viral factors. The aim...
7.
Chang X, Liu X, Martina B, Zeltins A, Augusto G, Vogel M, et al.
Front Immunol
. 2023 Feb;
14:1114396.
PMID: 36845100
Introduction: SARS-CoV-2 has developed a number of Variants of Concern (VOC) with increased infectivity and/or reduced recognition by neutralizing antibodies specific for the receptor binding domain (RBD) of the spike...
8.
Vogt A, Jorg L, Martina B, Krenger P, Chang X, Zeltins A, et al.
Front Immunol
. 2022 Jul;
13:864718.
PMID: 35784292
mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for...
9.
Vogt A, Augusto G, Martina B, Chang X, Nasrallah G, Speiser D, et al.
Vaccines (Basel)
. 2022 May;
10(5).
PMID: 35632499
In this report, we mechanistically reveal how the Variant of Concern (VOC) SARS-CoV-2 Omicron (B.1.1.529) escapes neutralizing antibody responses, by physio-chemical characterization of this variant in comparison to the wild-type...
10.
Mulgaonkar N, Wang H, Mallawarachchi S, Ruzek D, Martina B, Fernando S
J Biomol Struct Dyn
. 2022 Feb;
41(7):3052-3061.
PMID: 35220926
The rapid geographic expansion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infectious agent of Coronavirus Disease 2019 (COVID-19) pandemic, poses an immediate need for potent drugs. Enveloped viruses...